Agilent Technologies and Applied Proteomics to Maximise Protein Assays capabilities  

Agilent Technologies Inc. and Applied Proteomics Inc. are to collaborate on highly multiplexed protein assays and workflow solutions for multiple reaction monitoring through mass spectrometry. Proteins perform many important cellular functions, are the targets of most drugs and therapies, and are often used as biomarkers for detecting and monitoring disease.

“The ability to quickly and accurately measure, monitor and analyse a large number of protein biomarkers in a single test has important applications for understanding human diseases and developing new clinical diagnostics,” said John E. Blume Ph.D, chief science officer of Applied Proteomics. “Agilent’s innovation in mass spectrometry is an important part of this collaboration as we work together to expand the capabilities of multiplex protein assays.”

“We are thrilled to be collaborating with Applied Proteomics, an organisation that has leading expertise in developing mass spectrometry-based methods and instrumentation technologies for protein quantification and proteome applications,” said Can Ozbal, director of Agilent’s RapidFire business. “Agilent’s innovative automation, measurement and software platforms transform complete workflow solutions from sample preparation through data acquisition, analysis and evaluation in quantitative proteomics and biomarker validation."